Additionally, small molecule inhibitors targeting the interaction between endoglin and TGF-β ligands include compounds like AVID200, which is designed to selectively neutralize TGF-β1 and TGF-β3, playing a significant role in fibrosis and cancer pathologies (see above for details). The gene discussed is TGFB1; the disease is cancer.